A nanosuspension comprising (a) a pharmaceutical active ingredient or nutraceutical active ingredient having low solubility; (b) at least one alginate selected from the group consisting of (i) sodium alginate having a viscosity of 100 mPa.Math.s or less in a 1% solution in water at 20° C. and (ii) potassium alginate; and (c) water. Also, a drug dosage form prepared from such a nanosuspension.

The present invention relates to a process to prepare solid pharmaceutical forms comprising a quantity of mesalazine comprised between 75 and 95%, i.e. between 1000 and 1600 mg of drug per dosage unit. Furthermore, the present invention relates to a granulate and/or tablets obtained/obtainable with the process according to the invention, preferably coated to allow the controlled release of the drug. Finally, the present invention relates to the use of the granulate and/or the tablets as a medicament, preferably for the treatment of chronic inflammatory pathologies that preferably affect the intestinal tract.

Provided herein are pharmaceutical compositions (e.g., oral dosage formulations) comprising (S)-2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dione, or an enantiomer, mixture of enantiomers, tautomer, isotopolog, or pharmaceutically acceptable salt thereof, and a carrier or diluent. Also provided herein are methods of preparing and methods of using the pharmaceutical compositions.

This invention relates to a 19-nor C3,3-disubstituted C21-pyrazolyl steroid of formula (I) and pharmaceutical compositions thereof. Also disclosed herein are methods of making the pharmaceutical compositions of the 19-nor C3,3-disubstituted C21-pyrazolyl steroid of formula (I) and methods of using the 19-nor C3,3-disubstituted C21-pyrazolyl steroid of formula (I) or crystalline solid forms, pharmaceutically acceptable salts, and pharmaceutically acceptable compositions thereof.

A dry stable effervescent co-processed excipient composition comprising: (i) about 0.1 to about 50 wt. % of one or more carbonate bases selected from the group consisting of alkali carbonate, alkali bicarbonate, alkaline earth carbonate, alkaline earth bicarbonate and mixtures thereof; (ii) about 0.1 to about 50 wt. % of a water soluble carbohydrate sugar alcohol and; (iii) about 0.001. to about 40 wt % of one or more organic acids. Also disclosed is a process for preparing the composition.

The present disclosure relates to compositions including a phenylbutyrate compound and a bile acid, and methods of processing such compositions.

Provision of a granular preparation that contains edoxaban or a pharmacologically acceptable salt thereof, and has the property of being rapidly dissolved or suspended by the addition of water. A granular preparation comprising first granules containing (A) edoxaban or a pharmacologically acceptable salt thereof, (B) a sugar alcohol, and (C) a water-swelling additive, and second granules containing (D) 0.5 to 10% by weight of carmellose sodium with respect to the total weight of the preparation, and (E) 70 to 90% by weight of xylitol or sorbitol with respect to the total weight of the preparation.

A pharmaceutical composition comprising Compound 1, (3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid), and at least one excipient selected from: a filler, a disintegrant, a surfactant, a binder, and a lubricant, the composition being suitable for oral administration to a patient in need thereof to treat a CFTR mediated disease such as Cystic Fibrosis. Processes of preparing pharmaceutical compositions comprising Compound 1 are also disclosed.

An oseltamivir formulation and a preparation method of the formulation, the method being simple to operate, having good reproducibility, and being suitable for manufacture. The oseltamivir formulation includes oseltamivir or a salt thereof and a sustained-release material. The formulation may be a single-phase release formulation, a dual-phase release formulation, a three-phase release formulation, or a multi-phase release formulation having more than three phases. The formulation is administered once-daily and can achieve sustained release of at least 24 hours or longer, which can reduce the times of administration and avoid peak-to-valley fluctuations, thereby improving the compliance and safety of patients.

The present invention includes compositions and methods for making and using a rapid dissolving, high potency, substantially amorphous nanostructured aggregate for pulmonary delivery of tacrolimus and a stabilizer matrix comprising, optionally, a polymeric or non-polymeric surfactant, a polymeric or non-polymeric saccharide or both, wherein the aggregate comprises a surface area greater than 5 m.sup.2/g as measured by BET analysis and exhibiting supersaturation for at least 0.5 hours when 11-15-times the aqueous crystalline solubility of tacrolimus is added to simulated lung fluid.